Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome

Benralizumab, an interleukin-5 receptor blocker, significantly reduced absolute eosinophil counts and relieved symptoms in a small group of patients with hypereosinophilic syndrome. Adverse events were similar in the benralizumab group and the placebo group.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 380; no. 14; pp. 1336 - 1346
Main Authors Kuang, Fei Li, Legrand, Fanny, Makiya, Michelle, Ware, JeanAnne, Wetzler, Lauren, Brown, Thomas, Magee, Tamika, Piligian, Brent, Yoon, Pryscilla, Ellis, Jamie H, Sun, Xiaoping, Panch, Sandhya R, Powers, Astin, Alao, Hawwa, Kumar, Sheila, Quezado, Martha, Yan, Li, Lee, Nancy, Kolbeck, Roland, Newbold, Paul, Goldman, Mitchell, Fay, Michael P, Khoury, Paneez, Maric, Irina, Klion, Amy D
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 04.04.2019
Subjects
Allergies
Asthma
Bone marrow
Clinical trials
Cytokines
Double-blind studies
Drug dosages
Eosinophilia
FDA approval
Headache
Immunosuppressive agents
Infectious diseases
Interleukin 5
L-Lactate dehydrogenase
Lactic acid
Leukocytes (eosinophilic)
Monoclonal antibodies
Patients
R&D
Research & development
Online AccessGet full text

Cover

More Information
Summary:Benralizumab, an interleukin-5 receptor blocker, significantly reduced absolute eosinophil counts and relieved symptoms in a small group of patients with hypereosinophilic syndrome. Adverse events were similar in the benralizumab group and the placebo group.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1812185